UNSPSC 51422108: Mometasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HR4QJ6DW8, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11beta,16alpha)- but generally known as mometasone, which bears US NIH Compound Identifier 123620. European Medicines Agency schedules Mometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09045MIG.

UNSPSC 51422108 Mometasone is a Commodity code that, based on recent state and local solicitation activity, does not reflect the pharmaceutical products actually being procured under this code's designation. The single recent opportunity tagged to this code — Seminole County, Florida's procurement of naloxone and safe drug deactivation systems — involves emergency-response pharmaceuticals and harm-reduction equipment unrelated to mometasone, a corticosteroid used for allergic and inflammatory conditions. State and local governments appear to use this code inconsistently or the source does not capture procurement activity aligned with mometasone's actual therapeutic scope. The issuing body in the available record is a county health department, suggesting that when the code does see use, it targets public-health entities managing community health programs.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding with a response deadline of July 26, 2023, and quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract structure includes a two-year initial term with a one-year renewal option, fixed-fee pricing, and standard compliance requirements including E-Verify authorization, workers' compensation and general liability insurance, and potential FEMA funding with attendant federal environmental compliance obligations. Beyond this single opportunity, no other recent state or local mometasone procurement activity appears in the source, making current market assessment under this code limited.